NovaBay Pharmaceuticals, Inc.

NBY NYSE CIK: 0001389545

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608
Mailing Address 2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608
Phone (510) 899-8800
Fiscal Year End 1231
EIN 680454536

Financial Overview

FY2024

$3.42M
Total Assets
$10.55M
Stockholders' Equity
$2.92M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 12, 2026 View on SEC
DEF 14A Definitive proxy statement February 10, 2026 View on SEC
8-K Current report of material events January 30, 2026 View on SEC
4 Insider stock transaction report January 29, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 29, 2026 View on SEC
8-K Current report of material events January 28, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 21, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 21, 2026 View on SEC
8-K Current report of material events January 20, 2026 View on SEC
424B5 Prospectus supplement January 20, 2026 View on SEC

Material Events

8-K Strategy Change February 12, 2026
High Impact
  • Aims to meet NYSE American's $1.00 minimum bid price to avoid delisting.
  • Designed to attract broader institutional investment by increasing per-share price.
View Analysis
8-K Financial Distress January 28, 2026
High Impact
  • NovaBay's independent auditor, WithumSmith+Brown, PC, has stepped down, confirming the company's dissolution path.
  • The auditor's decision was not due to disagreements but directly stems from NovaBay's stockholder-approved plan of dissolution.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.